Levosimendan Tillomed

Levosimendan, the active ingredient in Levosimendan Tillomed, is a calcium sensitizer / inodilator presented as an intravenous formulation for intravenous use. It is employed to improve cardiac contractility and reduce symptoms in patients with acute decompensated heart failure, particularly when conventional therapy is insufficient.

GNH USA supplies Levosimendan Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to healthcare institutions across global markets.

Levosimendan is indicated for conditions within the heart failure spectrum where enhanced cardiac output is required.

- Acute decompensated heart failure: improves cardiac output and relieves pulmonary congestion. - Chronic heart failure (intermittent infusion): provides temporary hemodynamic support and may improve functional status. - Low cardiac output syndrome after cardiac surgery: stabilizes hemodynamics and facilitates weaning from mechanical support.

Levosimendan may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Hypotension: drop in blood pressure, especially after loading dose. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate. - Vomiting: occasional.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: chest pain due to reduced coronary perfusion. - Severe hypotension: refractory low blood pressure requiring intervention. - Allergic reactions: rash, pruritus, or anaphylaxis. - Pulmonary edema worsening: paradoxical fluid accumulation.

When using levosimendan, several safety considerations should be observed.

- Blood pressure monitoring: check systolic pressure before and during infusion. - Cardiac rhythm surveillance: observe for arrhythmias, especially in patients with pre‑existing conduction disorders. - Renal function assessment: adjust therapy in severe renal impairment. - Hepatic function assessment: use caution in moderate to severe liver disease. - Contraindication in severe hypotension: avoid if systolic BP < 90 mmHg. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan can interact with several concomitant medicines; interactions are grouped by clinical significance.

Major Interactions (Avoid): - Concurrent use with other potent vasodilators (e.g., nitroglycerin): may cause profound hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase levosimendan plasma levels. - Other inotropes (e.g., dobutamine) at high doses: risk of excessive cardiac stimulation.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt desired inotropic effect. - Diuretics: synergistic effect on blood pressure, monitor volume status. - Anticoagulants (e.g., warfarin): possible alteration in bleeding risk, monitor INR.